Can Pre-Operative Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Non-Metastatic Renal Carcinoma Recurrence after Nephrectomy? (UroCCR-61 Study).
bio-marker
localized RCC
neutrophil–lymphocyte ratio
prognostic factor
renal cell carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Nov 2022
19 Nov 2022
Historique:
received:
04
10
2022
revised:
15
11
2022
accepted:
17
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Recent studies suggested that the neutrophil-to-lymphocyte ratio (NLR) could play a key role in tumor initiation, progression and response to treatments. The main objective was to assess the prognostic value of the pre-operative NLR on recurrence-free survival (RFS) in patients with non-hereditary localized renal cell carcinoma. From the UroCCR database (NCT03293563), factors influencing the disease recurrence of consecutive patients who underwent nephrectomy for cT1-T4 N0M0 were analyzed using multi-variate cox regression and log-rank methods. We included 786 patients, among which 135 (17.2%) experienced a recurrence at a median time of 23.7 [8.5-48.6] months. RFS for patients with a pre-operative NLR of <2.7 was 94% and 88% at 3 and 5 years, respectively, versus 76% and 63% for patients with a NLR of ≥2.7 (
Identifiants
pubmed: 36428784
pii: cancers14225692
doi: 10.3390/cancers14225692
pmc: PMC9688470
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Prog Urol. 2020 Nov;30(12S):S2-S51
pubmed: 33349425
J Urol. 2010 Sep;184(3):873-8
pubmed: 20643463
Br J Cancer. 2013 Mar 5;108(4):901-7
pubmed: 23385728
Urol Oncol. 2017 Apr;35(4):135-141
pubmed: 28233671
BJU Int. 2007 Feb;99(2):296-300
pubmed: 17326263
Asian Pac J Cancer Prev. 2015;16(9):3703-8
pubmed: 25987025
J Clin Oncol. 2004 Aug 15;22(16):3316-22
pubmed: 15310775
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
N Engl J Med. 2021 Aug 19;385(8):683-694
pubmed: 34407342
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
J Urol. 2012 Feb;187(2):411-7
pubmed: 22177153
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Urol Ann. 2014 Apr;6(2):116-21
pubmed: 24833821
Urol Oncol. 2014 Nov;32(8):1277-84
pubmed: 25017696
Can Urol Assoc J. 2018 Jul;12(7):E345-E348
pubmed: 29603920
J Urol. 2013 Dec;190(6):1999-2004
pubmed: 23831313
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Immunotherapy. 2019 May;11(7):631-643
pubmed: 30943858
World J Urol. 2017 Feb;35(2):261-270
pubmed: 27255479